Freedom to Live Life Fully

KORU™ MEDICAL SYSTEMS

A Global Leader in Large-Volume Subcutaneous Drug Delivery

Nasdaq: KRMD

Corporate Overview

May 2025

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements, including, but not limited to, timing of 510(k) clearances and financial guidance for fiscal 2025.

Forward-looking statements discuss the Company's current expectations and projections relating to its financial position, results of operations, plans, objectives, future performance, and business. Forward-looking statements can be identified by words such as "guidance", "expect", "plan", "believe" and "will". Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance.

The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, uncertainties associated with SCIg market growth, prefilled syringe penetration, plasma supply, clinical trial activity and success, approval and commercialization of new drug indications, the shift to increased healthcare delivery in the home, new patient diagnoses, customer ordering patterns, global health crises, innovation and competition, labor and supply price increases, inflationary impacts, labor supply, tariffs and those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which are on file with the SEC and available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the attachments is as of May 7, 2025. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

Revenues: All references to revenue(s) in this presentation refer to net revenues.

Our Company

We enable, simplify, and enhance the delivery of large-volume subcutaneous (LVSC) drugs in the home and in the clinic

KORU's Freedom Infusion System is a **global leader in large-volume (>10mL) drug delivery**

Capitalizing on the ongoing shift from intravenous (IV) hospital settings to **subcutaneous (SC) therapy in the home and in infusion clinics**

Our subcutaneous Freedom Infusion System is, today, primarily used by **45,000 chronic, recurring** subcutaneous immunoglobulin (SCIg) drug therapy patients

Expanding our market beyond SCIg via 9 current collaborations with pharmaceutical companies to bring **new drug therapies** onto our label

Leveraging a low cost go-to-market model by serving pharmaceutical companies, specialty pharmacies, home care networks, and distributors

Our Company

KORU at a Glance

FREEDOM INTEGRATED INFUSION SYSTEM

70+ Global Patents

DRUG CLEARANCES / REGISTRATIONS

8 Drugs / 36 Countries

First Subcutaneous Drug Clearance 2010

FY 2024 REVENUES

$33.6M[1]; 18% y/y growth

75%+ Recurring

FY24 CASH BURN $1.8M, $10M UNDRAWN DEBT FACILITY IN PLACE

$8.7M Cash Balance[1]

HEADQUARTERS/MANUFACTURING

Mahwah, NJ



FY2024 REVENUES

$33.6M[1]

- Domestic Core
- International Core
- Pharma Services & Clinical Trials

Pharma Services and Clinical Trials

Revenue from pre-commercial pharmaceutical drug collaborations utilizing Freedom Infusion System

Clinical Trial Supplies

Non-Recurring Engineering Services

FKA Novel Therapies

Domestic & International Core

Freedom Infusion System sales for on-label commercialized drugs

Pharmaceutical drug collaborations move to Core business following 510k clearance for use of the drug with the KORU Freedom Infusion System

1. As of Q1 Earnings Press Release published on May 7, 2025

Our Company

KORU's Freedom Infusion System

Mechanical Pumps
~20% of revenues

Freedom60® INFUSION SYSTEM

FreedomEDGE® INFUSION SYSTEM

Customizable Consumables
~80% of revenues



Precision™ FLOW RATE TUBING



High-Flo™ SUBQ NEEDLE SET

Simple, Easy-to-use, Reusable mechanical pump

8 On-label SC drugs[1]

2M+ annual infusions, 45k+ recurring chronic patients (ages 6-93)

97% Patient adherence rate[2]

Customizable platform for use with large-volume SC drugs

Registered in 36 countries

1. Includes CSL Hizentra, Octapharma Cutaquig and Gammanorm, Takeda Cuvitru, Hyqvia and Gammagard Liquid, Grifols Xembify, and Apellis Empaveli 2. Rutland B, Bosshard J, Southworth C. Enhancing Drug Adherence and Patient Outcomes: The Role of SCIG Pump Selection in Subcutaneous Immunoglobulin Therapy for Primary Immunodeficiency Disease. Poster presented at: National Home Infusion Association Annual Conference; March 23-27, 2024; Austin TX.

SC Landscape

Shift from IV to SC is Driving a Sizeable and Growing Market of Large-Volume Subcutaneous (LVSC) Opportunities



1

- On label w/KORU Freedom Infusion System
- On label w/on-body infusion device
- Drugs administered with manual push syringe
- Drugs administered with e-pump system
- Pre-Commercial[2]
- In Clinical Development

7 LVSC drugs have launched between 2010-2019, 6 of which were in the Ig drug class and approved with the KORU Freedom Infusion System

Between 2020-2025, 10 drugs have launched, and the LVSC market has diversified, primarily in oncology

There are 15+ new drugs in the clinical pipeline as pharma companies are increasingly adding SC formulations

1. Third Party Data on File 2. Timing based on pharma company estimates

KORU's Opportunity

KORU is Well Positioned to Capitalize on the Expanding SC Market Opportunity

Market Proven Freedom Infusion System

Proven system with 15+ years on market; 2.2M+ infusions annually, underlying US market growing 8-10%[1]

Simple, reusable and fully reimbursed system with 97% adherence rate and 8 on-label SC drugs

Thousands of trained healthcare professionals to enable transition from hospital to home

Efficient, Scalable Go-to-Market Strategy

SC drug prescriptions driven by pharma companies; allows efficient scaling without related spend for KORU

KORU manufactures and sells to distributors who market directly to specialty pharmacies and homecare networks

Razor-Razor Blade Model; 75%+ Recurring Revenue

Pump hardware lasts 3+ years; disposable SC infusion consumable sets used weekly and drive recurring revenue

Consumables compatible with mechanical and e-pumps

$2.7B TAM with Ig and New Drug Indications

Fully customizable system to accommodate any SC drug above 10ml with proven safety and commercial success

Expanding beyond $500M global Ig market with new drug therapy areas adding additional $2.2B in TAM[2]

5 launched oncology infusion clinic drugs using manual syringe push method of delivery present further opportunity

1. KORU Medical Estimates and Third-Party Data on File 2. TAM based on patient population, expected treatment frequency. Not adjusted for clinical risk

KORU's Opportunity

$2.7B[1] Total Addressable Market Opportunity with Growing SCIg Market and Expansion to New Drug Therapies

8 SC Drugs Currently on KORU's Freedom Infusion System (primarily Ig)

cutaquig®
gammanorm®
Cuvitru
Hizentra®
EMPAVELI™
HyQvia
GAMMAGARD LIQUID
Xembify® (immune globulin subcutaneous human-klhw) 20%

+ an Additional 6 Ig Device/Indication Collaborations

$500M Ig TAM[1]
Growing 8-10% /year

9 Active Collaborations to add New Drugs/Indications to KORU's Freedom Infusion System

Across 6 Drug Therapy Areas

- 1 in Oncology
- 4 in Nephrology
- 1 in Rare Disease
- 1 in Endocrinology
- 1 in Respiratory
- 1 in Hematology

$2.2B TAM[1]

KORU's Future Opportunities in Clinical-Stage and Commercialized Large-Volume SC Drugs

Other	2
Central Nervous	5
Immunology	5
Oncology	6

Opportunity for Significant TAM Expansion

1.TAM based on patient population, expected treatment frequency. Not adjusted for clinical risk

KORU's Opportunity

Strategic Growth Pillars

Key Drivers

3 — Add New Drugs on Label Through Novel Therapies Pipeline

~$2.2B TAM[1]

5 new SC Drugs expected to be commercialized and added to KRMD label by 2027

Novel Therapies Pipeline

- 5 new drug approvals expected by 2027
- 9 current new drug collaborations
- Entering infusion clinics in 2025
- 15 pipeline opportunities

2 — Expand Internationally

~$265M TAM[1]

10% market share, growing at or above market rates (8-10%)[2] with multiple opportunities for growth

International Ig

- Multiple top-10 new market entries and increased market penetration
- Increased SCIg new patient starts
- Pre-filled syringe launches
- Next-gen pump and consumables launch
- Pharmaceutical partnerships for new indications/devices driving share expansion
- Broader partnerships

1 — Defend & Grow Leadership Position in Domestic Subcutaneous Ig

~$235M TAM[1]

Strong base business with leading market share[1], growing at or above market rates (8-10%)[2] targeting additional market share capture

Domestic Ig

- Increased SCIg new patient starts
- Continued shift towards pre-filled syringes
- Next-gen pump and consumables launch
- Pharmaceutical partnerships for new indications/devices driving share expansion
- New market entries

KORU

1. TAM based on patient population, expected treatment frequency. Not adjusted for clinical risk 2. KORU Medical Estimates and Third-Party Data on File

KORU's Opportunity

Global Ig Business Drives Annual Recurring Revenue Base

Global Patient Base

45k+ Patients using the KORU Freedom Infusion System today, representing 2M+ annual recurring infusions

Current 510k Clearances

8 SCIg drugs from 5 major pharmaceutical manufacturers cleared for use on the KORU Freedom Infusion System



Chronic Disease with Weekly Recurring Treatments

Chronic disease (PIDD, CIDP, etc.) patients receive SCIg doses 1-2x per week for the remainder of their lives

6 New Ig Pharmaceutical Collaborations

New indications and devices give us opportunity to expand our market share and geographic reach

$500M TAM[1] — Global Ig market totals $500M TAM; 20% penetrated by SC (vs 80% IV)

8-10% Market growth[2] — SCIg Market is growing 8-10% year globally; new patients begin treatment protocol annually

≈$750-$1,000 Annual revenue per patient — Recurring revenue generated by each Ig patient on the KORU Freedom Infusion System; based on 1x pump sales + weekly consumables

1. TAM based on patient population, expected treatment frequency. Not adjusted for clinical risk 2. KORU Medical Estimates and Third-Party Data on File

KORU's Opportunity

75% Recurring Revenues from a Growing Patient/Infusion Base



Strong Recurring Base that is Expected to Grow

75% of KORU's revenue is recurring
Removing initial 1x sale of pumps and PST service revenue

Recurring SCIg patient base
~45k+ KORU chronic SCIg patients
~2M+ KORU annual infusions

KORU outperforming market growth[1]
8-10% US SCIg Growth
Outperformance driven by share gains and new market entries

1. Third party data & KORU Medical estimates

Future Catalysts

Robust Pipeline With Multiple Near-Term Opportunities

17 Opportunities / 15 Collaborations | **9 Commercial Opportunities by 2026** | **$2.7B[1] Addressable Market Combined**

Immunology New Indications/New Devices

Asset	Drug Trial Phase	Next Step	Expected KRMD Clearance[2]	Patient Population (000s)
Freedom Japan Clearance	Launched	Commercialization	2025	630
Ig Device	Launched	KRMD 510k	2026	
Ig Device	Launched	KRMD 510k	2026	
Ig Device	Launched	KRMD 510k	2026	
Ig Drug	●●●	Complete Phase III	2027/28	
Ig Drug	●○○	Entry to Phase II	2027/28	

Opportunity for Increased Market Share and Geographic Penetration in Ig

New Drug Potential Launches

Pipeline Updates

Asset	Drug Trial Phase	Next Step	Expected KRMD Clearance[2]	Patient Population (000s)	Est. Total Annual Infusions[3]
Rare Disease Biologic	Launched	KRMD 510k	2025	65	~100k
Nephrology Drug	●●●	FDA Approval	2025	3	~20k
Iron Chelation Drug	Launched	KRMD 510k	2025/26	TBD	TBD
Antibiotic Drug	Launched	KRMD 510k	2025/26	TBD	TBD
Oncology Drug	Launched	KRMD 510k	2026	500	~800k
Nephrology Drug	●●●	Complete Phase III	2027	30	~300k
KIRA (PNH)	●●●	Entry to Phase III	2027/28	133	TBD
Endocrinology Drug	●●●	Complete Phase III	2028	10	TBD
Respiratory Drug	●●○	Complete Phase II	2028/29	239	TBD
KIRA (IgAN)	●●○	Complete Phase II	2029/30	540	TBD
KIRA (C3G)	●●○	Complete Phase II	2029/30	2	TBD

Commercial Revenue Opportunity from New Drugs and Indications on our Label

KORU

1.TAM based on patient population, expected treatment frequency. Not adjusted for clinical risk 2. Clearance and launch dates are based on most recent estimation and are subject to change 3. Annual infusions are estimates at 3 years post drug launch

Financials & Outlook

Financial Highlights



2024 Revenue

$33.6M; 18% y/y growth

14.5% Revenue CAGR

More than tripled size of Company in 10 years

Cash Flow Positive in Q4 2024

FY24 cash burn of $1.8M, a 68% improvement from ’23-’24

Cash & Cash Equivalents*

$8.7M cash on hand, $10M undrawn debt facility in place

Q1 2025 Financial Highlights

	Q1 2025	Q1 2024	Y/Y Δ
Revenue	$9.6M	$8.2M	18% Growth
Gross Margin	62.8%	62.3%	50bps Growth
OpEx	$7.3M	$7.1M	3% Increase
Net Loss	($1.2M)	($1.9M)	40% Improvement
Adj. EBITDA	($0.2M)	($0.9M)	80% Improvement
EPS	($0.03)	($0.04)	25% Improvement
Cash Burn	($0.8M)	($0.7M)	14% Increase

KORU

1. As of Q1 Earnings Press Release published on May 7, 2025

Financials & Outlook

Financial Profile



1. As of Q1 Earnings Press Release published on May 7, 2025 2. Per most recent strategic plan

Our Company

Strong Foundation; Experienced Pharma and MedTech Leadership Team Focused on Execution

- 44,000 sq. ft. Facility:
  - Class 8 cleanrooms
  - Controlled manufacturing environment
  - R&D laboratory space
  - In-house distribution center
- ISO 13485/MDSAP/EU MDR Certified Quality Management Systems
- Successful Notified Body and Pharmaceutical customer audit outcomes

LINDA THARBY
Chief Executive Officer & President

TOM ADAMS
Chief Financial Officer

Chris Pazdan
Chief Operating Officer

ROB CANNON
Interim Chief Commercial Officer

BRENT RUTLAND
Vice President of Medical Affairs

BRIAN HERTZOG
Vice President of Biopharma Business Development

Baxter BD Pfizer Roche

Nemera McKESSON La Jolla Pharmaceutical

Outlook

Key 2025 Milestones

Financial Targets and Guidance

- $38.5-39.5M ; mid teens growth
- Positive cash flow from operations for FY2025
- Adj. EBITDA growth, higher gross profit, increased operating leverage

Add New Drugs to Label through Novel Therapies Pipeline

- 3 new pharmaceutical collaborations (2 of 3 complete)
- 510(k) submission Iron Chelation Drug (2H 2025)
- 510(k) submission Antibiotic Drug (2H 2025)
- 510(k) submission Rare Disease Drug for infusion clinic (2H 2025)
- 510(k) submission Oncology Drug for infusion clinic (Q4 2025 – Q1 2026)

Expand Internationally

- Japan Commercial Sales 1H 2025
- Phase 1 flow controller launch Q3 2025
- 510(k) submission Phase 2 flow controller Q1 2026
- Further top-10 market entries

Defend & Grow Domestic SCIg

- Sustained 8-10% SCIg drug market growth
- 510(k) submission new consumables (2H 2025)
- 510(k) submission next gen. pump (Q4 2025 – Q1 2026)



KORU Medical

Strategic Highlights Summary

1. **Macro tailwinds** driving **adoption of subcutaneous therapy**; many large-volume SC drugs in development by major Pharma companies in multiple indications

2. 21% growth in Core business with **75% recurring revenues**

3. **Strong underlying SCIg market**; gaining greater market share domestically and **expanding into other top-ten global markets**

4. **9 potential commercial opportunities (drugs, indications, and devices) by 2026**; oncology and rare disease indications will **expand our presence outside of the home and into infusion clinics**

5. **Raising 2025 revenue guidance,** maintaining gross margin and positive cash flow from operations targets

KORU™
MEDICAL SYSTEMS

Back Up

Oncology Infusion Clinic Opportunity

97% of Nurses Prefer KORU Freedom System for Subcutaneous Oncology Infusion[1]

Nursing Preference Study: FreedomEdge® vs Manual Syringe Administration

Over 3,000 patients in 6 hospitals received KORU FreedomEdge® infusions from 33 nurses who had previously administered the same >10mL drug via manual push

97% of nurses reported **increased patient interaction** while using the FreedomEdge® Infusion System

81% of nurses experienced **less hand pain** compared to manual syringe administration

91% of nurses found KORU FreedomEdge® Infusion System **easier to use** compared to manual syringe administration

73% of nurses **observed less patient pain** while using FreedomEdge® Infusion System

97% of nurses would recommend the KORU FreedomEdge® Infusion System over manual syringe in subcutaneous oncology infusions, citing ease of use and reduced discomfort as key reasons

1 KORU Medical Nursing Study Data as Presented at PODD on October 28, 2024

Market Opportunity

Key Drivers in the Move from IV to SC Administration

Therapeutic Benefits

30g 5% IVIg Tri-Weekly vs 12g 16% SCIg Weekly



Constant Ig levels with SC vs peaks & valleys in IV→ fewer adverse reactions and infections for patients[1]

Patient Preference



85% of patients choose SC over IV naming less pain, faster infusion, and a less emotionally distressing process as reasons to switch[2]

Cost Savings

Monthly Cost of Administered Specialty Drugs for Privately Insured Individuals



(33-52%) savings when shifting site of care change from hospital to physician offices/home[3]

1. Berger M. Clin Immunol 2004;112:1-7 2. O'Shaughnessy et al Eur J Cancer 2021 3. UnitedHealth Group, Reducing Specialty Drug Costs, 2019

Outlook

New Product Launches: Catalysts for SCIg Share Gains and New Market Entries



Flow Controller

Phase 1 (Line extension)
- Q3 Launch
- Improved COGS and capacity

Phase 2 (Next generation product)
- 510k submission in 1Q26
- Increased performance and accuracy
- Expanded label indications in new markets

New Consumables Sets

- 510k submission in 2H25
- Improved patient comfort and convenience
- Customizable platform for new drugs

Next Generation Pump

- 510k submission (4Q25-1Q26)
- Accommodates all available PFS 5mL to 50mL and vial/syringe compatible
- Improved patient mobility, ease of use, and dosing feedback
- Opens new geographic markets

Flow Controller 2H25 Driver; Pump and Consumables FY26 Driver

KORU

Non-GAAP Financial Measures

This presentation includes the non-GAAP financial measures “adjusted EPS”, "adjusted diluted EPS“, and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on KORU Medical's reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company's financial results. Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results. Reconciliations of the Company's non-GAAP measures are included at the end of this presentation.

Reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA:	**Three Months Ended March 31, 2025**	**2024**
GAAP Net Loss	$ (1,166,237)	$ (1,935,958)
Depreciation and Amortization*	217,357	231,369
Interest (Income), Net	(73,180)	(37,187)
Reorganization Charges	—	99,329
Litigation Expense	133,411	
Stock-based Compensation Expense*	697,590	699,718
Non GAAP Adjusted EBITDA	$ (191,059)	$ (942,729)
Weighted average number common shares	45,981,826	45,712,224

Reconciliation of Reported Diluted EPS to Non-GAAP Adjusted Diluted EPS:	**Three Months Ended March 31, 2025**	**2024**
Reported Diluted Earnings Per Share	$ (0.03)	$ (0.04)
Depreciation and Amortization*	—	0.01
Interest (Income)/Expense, Net	—	—
Reorganization Charges	—	—
Litigation Expense	—	—
Stock-Based Compensation Expense*	0.02	0.02
Non GAAP Adjusted Diluted Earnings Per Share	$ 0.00	$ (0.02)

KORU *Non-cash items